ArticleOncoTargets and therapy2015

A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation.

Yuguo Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.